Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.




This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Kenneth Edelson

Owner
Kenneth Edelson, MD
Member of the Healthcare Council

Kenneth Edelson, MD, FAACS, is a Dermatologist in private practice in New York. Dr. Edelson specializes in skin cancer as well as cosmetic dermatology, including lasers and IPL's for facial rejuvenation and skin tightening, vascular lesions, pigmentation, and cellulite. He also uses lasers for leg veins as well as sclerotherapy. He has presented cases to organizations such as the Atlantic Dermatologic Conference, Metropolitan Dermatology Society of New York, and the New York Academy of Medicine. He has served as a Clinical Investigator for The Collagen Corporation and has helped in launching the "first" filler, Zyderm. Dr. Edelson has extensive experience with all fillers, including Juvederm, Restylane, Radiesse and Botox, and is an expert in treating and diagnosing skin cancer. (This is me - Update Profile)


Employment History
1980 - present Owner
Kenneth Edelson, MD

GLG Study Groups with Kenneth Edelson(?)

View All Study Groups with Kenneth Edelson

GLG NewsSM Analyses by Kenneth Edelson(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
Cost is key, but not enough! | 12-17-2007
Analysis of: Ipsen and Medicis announce submission of Reloxin(R) in aesthetics to the FDA | www.pipelinereview.com
Author: Kenneth Edelson, Owner, Kenneth Edelson, MD

Lowering cost of Botox is key, but not enough to induce patients to undergo Botox treatments.

Reloxin Gives Allergan's Botox A Run for the Money! | 12-13-2007
Analysis of: Ipsen and Medicis announce submission of Reloxin(R) in aesthetics to the FDA | www.pipelinereview.com
Author: Kenneth Edelson, Owner, Kenneth Edelson, MD

For too long Allergan has monopolized the therapeutic and cosmetic market of botulinum toxin type A, and has taken full advantage of that monopoly by raising the price of Botox almost biannually. Reloxin studies are very favorable when compared to Botox, and may even surpass it in one or two aspects....

New Organiceuticals May Help Bring Back Beauty! | 05-29-2007
Analysis of: http://www.nytimes.com/2007/04/26/fashion/26skin.html?_r=1&ref=health&oref=slogin | www.nytimes.com
Author: Kenneth Edelson, Owner, Kenneth Edelson, MD

All that glitters is not gold...but some might be! Anti-oxidants are the promise of saving our "hides"!

Couldn't agree more | 05-28-2007
Analysis of: FDA May Place Ban on OTC Bleaching Creams | www.carefair.com
Author: Kenneth Edelson, Owner, Kenneth Edelson, MD

Keep Hydroquinones Around!

View All GLG News SM Analyses by Kenneth Edelson

GLG InstituteSM Seminars with Kenneth Edelson(?)

 
Kenneth Edelson has not participated in any GLGi Seminars.
View all GLG InstituteSM Seminars in Healthcare

Request a project with Kenneth Edelson









Note: GLG Experts do not provide personal medical advice, diagnosis or treatment through this site.

GLG's 750+ Clients Include:

40 of the leading 50
global mutual funds
15 of the leading 20
global banks
8 of the leading 10
private equity firms
90%+ client subscription renewal rate

Analytics